املعارف واملواقف واملامرسات لدى الصيادلة والعاملني يف الرعاية الصحية حول االستخدام السليم ملانعات احلمل الفموية واآلثار اجلانبية وموانع االستعامل
|
|
|
- Peregrine Nicholson
- 9 years ago
- Views:
Transcription
1 املجلة الصحية لرشق املتوسط املجلد التاسع عرش العدد السادس Knowledge, attitude and practice of pharmacists and health-care workers regarding oral contraceptives correct usage, side-effects and contraindications M. Sattari, 1 Z. Mokhtari, 2 H. Jabari 3 and S.O. Mashayekhi 4 املعارف واملواقف واملامرسات لدى الصيادلة والعاملني يف الرعاية الصحية حول االستخدام السليم ملانعات احلمل الفموية واآلثار اجلانبية وموانع االستعامل حممد رضا ستاري زينب خمتاري حسني جباري سيمني عذار مشاخيي اخلالصة: الرغم من النجاح الذي حققه الربنامج اإليراين لتنظيم األرسة فإن عدد األمحال غري املرغوبة اليزال مرتفعا. وهيدف الباحثون للتعر ف عىل ما إذا كان العاملون الصحيون يف تربيز يقدمون املعلومات واملشورة الصحيحة حول استخدام مانعات احلمل الفموية. وهتدف هذه الدراسة للتعر ف عىل مستوى املعارف واملواقف واملامرسات لدى من يقد م مانعات احلمل الفموية. وشملت العينة 150 عامال صحيا يف البيوت الصحية و 150 صيدليا يف املجتمع أو يف املستشفى فأجابوا عىل استبيان حول املعارف عن االستخدام الصحيح ملوانع احلمل الفموية وآثارها اجلانبية وموانع االستعامل وعالمات وأعراض اخلطر وفوائدها غري املانعة للحمل وما إذا كانوا يقد مون املشورة للمرىض حول هذه املواضيع. واتضح أن معارف الصيادلة والعاملني الصحيني مل تكن مرتفعة وأهنم كانوا يقد مون املشورة للمرىض يف الكثري من املواضيع حتى عندما كانوا يفتقدون املعلومات غري الصحيحة ويف جماالت أخرى مل يكونوا يقد مون املعلومات للمرىض عىل الرغم من أهنم يملكون املعلومات الصحيحة. وخلصت الدراسة إىل أن التثقيف الصحي املستمر للقائمني عىل تقديم موانع احلمل الفموية والسي ام للصيادلة أمر يبدو رضوريا. ABSTRACT Despite the success of the Iranian family planning programme, the number of unwanted pregnancies remains high. To investigate whether health workers in Tabriz are providing correct information and about OCP use, the current study was planned to examine the level of knowledge, attitude and practice of OCP providers. A sample of 150 health-care workers in health houses and 150 community/hospital pharmacists answered a questionnaire about knowledge of correct use of OCP, side-effects, contraindications, danger signs/symptoms and non-contraceptive benefits, and whether they counselled patients about these subjects. Knowledge of pharmacists and health workers was not as high as expected and in many topics they were patients even when they had incorrect knowledge and in other areas they were not providing information to patients despite having the correct knowledge. Better continuing education for OCP providers and especially for pharmacists seems necessary. Connaissances, attitudes et pratiques des pharmaciens et des agents de soins de santé concernant l'utilisation correcte des contraceptifs oraux, les effets secondaires et les contre-indications RÉSUMÉ Malgré le succès du programme de planification familiale iranien, le nombre de grossesses non désirées reste élevé. Pour savoir si les agents de soins de santé à Tabriz fournissaient des informations et des conseils adaptés sur l'utilisation des pilules contraceptives, la présente étude a été planifiée pour examiner le niveau de connaissances, les attitudes et les pratiques des personnes qui dispensent des pilules contraceptives. Un échantillon de 150 agents de soins de santé dans des maisons de santé et de 150 pharmaciens en milieu hospitalier ou communautaire ont répondu au questionnaire évaluant leurs connaissances sur l'utilisation correcte des pilules contraceptives, les effets secondaires, les contre-indications, les signes de danger/symptômes et les avantages non-contraceptifs, mais aussi sur l'offre ou non de conseils aux patientes en la matière. Les connaissances des pharmaciens et des agents de soins de santé n'étaient pas aussi bonnes qu'escomptées. De plus, sur de nombreux sujets, ils conseillaient les patientes même lorsqu'ils avaient des connaissances erronées et dans d'autres domaines, ils s'abstenaient de proposer des conseils malgré la justesse de leurs connaissances. Améliorer la formation continue des des personnes qui dispensent des pilules contraceptives, et particulièrement des pharmaciens, semble nécessaire. 1 Research Centre of Infectious Disease and Tropical Medicine, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Islamic Republic of Iran. 2 Students Research Committee, Tabriz University of Medical Sciences, Tabriz, Islamic Republic of Iran. 3 Tabriz Health Services Management Research Center, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Islamic Republic of Iran. 4 Tabriz Health Services Management Research Center, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Islamic Republic of Iran (Correspondence to S. Mashayekhi: [email protected]). Received: 07/02/12; accepted: 06/05/12 547
2 EMHJ Vol. 19 No Eastern Mediterranean Health Journal La Revue de Santé de la Méditerranée orientale Introduction From a global perspective strategies are needed for controlling the rapid worldwide population growth of recent centuries [1,2], while from the individual perspective accurate and efficient methods are needed to prevent unwanted pregnancies and their adverse consequences [3]. Many factors play a role in the failure of contraception methods, including lack of knowledge about their use and side-effects. In order to provide users with useful information, health care providers need to be trained to transmit accurate and complete knowledge about contraception methods, and should be able to communicate adequately with users. According to an Iranian Ministry of Health report, the fertility rate in the Islamic Republic of Iran has decreased from 5.6 births/ woman in 1985 [4] to 1.8 births/women in 2009 [5]. This can be attributed to the Iranian family planning programme that was proposed in December 1989 and which provides free contraceptives to families via the primary health care delivery system [6]. Despite the success of this programme the number of unwanted pregnancies remains high [7], raising questions about women s compliance with contraceptive use. Oral contraceptives pills (OCP) are one of the most effective reversible methods of preventing unwanted pregnancies. In the Islamic Republic of Iran women can obtain OCP from 2 sources: government-run health houses or community/hospital pharmacies. In the health houses health-care workers (HCW), who include midwives and family/public health educators, provide birth control methods (e.g. OCP and condoms) to families and educate them about their use. They provide a limited range of low-cost generic OCP free-ofcharge to users. OCP are also dispensed by pharmacists in community or hospital outpatient pharmacies. In addition to the cheaper OCP pharmacies also sell the more expensive brand-name OCP. The aim of the current study was to examine the level of knowledge, attitude and practice of pharmacists and HCW who provide OCP to users in the Islamic Republic of Iran. Methods Study setting and sample Data were collected between November 2009 and October 2010 in Tabriz, Islamic Republic of Iran. All pharmacists and HCW working in Tabriz at the time of the study were invited to enter the study. The study was conducted during obligatory continuing medical education courses for pharmacists or monthly meetings for HCW. A total of 150 pharmacists and 150 HCW participated in the study Data collection The aims of the study were explained to the subjects and after obtaining written consent, they completed a questionnaire. A researcher was present at the time of completion of the questionnaires to answer any questions. The subjects were free to withdraw from the study at any time. All efforts were made to protect the participant s rights and confidentiality. The questionnaire was adopted from Gaudet et al. s research [8] and translated into Farsi language with a few changes. The final questionnaire comprised 34 items including 6 about demographic data, and the validity and reliability of the questions were tested on 50 subjects prior to the study (Cronbach α = 0.88). The questions were divided into the following sections: demographic information (age, sex, years of experience, education level); general knowledge about OCP (which OCP they provided/sold; reasons for recommending OCP; maximum duration for safe use of OCP; users health history prior to initiation of OCP; recommended checkups for users of OCP); and knowledge and about OCP use (how to initiate OCP and what to do about missed pills; non-contraceptive benefits of OCP; side-effects of OCP; controversies/myths regarding OCP; and serious dangers/risks of OCP). In the knowledge and section, respondents were asked to answer each knowledge topic (scored as correct, incorrect or no response) and whether they counselled patients about that topic (scored yes/no). The different types of OCP available on the Iranian market are: high-dose generic monophasics (50 µg ethinyl estradiol/0.5 mg norgestrel), low-dose generic monophasics (30 µg ethinyl estradiol/0.3 mg norgestrel), generic triphasics, levonorgestrel (breast-feeding OCP), Marvelon (30 µg ethinyl estradiol/150 µg desogestrel), Desoceptive (30 µg ethinyl estradiol/150 µg desogestrel), Yasmin (30 µg ethinyl estradiol/3 mg drospirenone), and cyproterone compound (35 µg ethinyl estradiol/2 mg cyproterone acetate). Analysis The results are reported as mean and standard deviation (SD), number and percentages. Student t-test and chisquared tests were used for analysis of quantitative and qualitative variables respectively, utilizing SPSS, version 15. A significant level of P < 0.05 was adopted for all tests. Results Demographic information The mean age of the pharmacists was 37.9 (SD 9.6) (range 23 77) years and of HCW was 37.0 (SD 4.6) (range 26 50) years with no significant difference between the 2 groups (P = 0.32). There was a significant sex difference between the groups; 47.3% of pharmacists and 100% of HCW were female (P < 0.001). The average work experience of pharmacists was 13.0 (SD 8.9) (range 1 53) years while HCW had 9.3 (SD 548
3 املجلة الصحية لرشق املتوسط املجلد التاسع عرش العدد السادس 5.5) (1 24) years of work experience (P < 0.05). The education level in the pharmacists group was DPharm in all cases but was bachelor or associate degree for 65.3% and 34.7% respectively of HCW. General knowledge about OCP Contraceptive low-dose generic OCP were sold/provided to users by 98.7% of both groups. In the pharmacists group the next most commonly sold formulations were high-dose generic OCP (91.3%), levonorgestrel (80.0%), triphasics (73.3%), Marvelon (65.3%), Yasmin (60.7%), Desoceptive (58.7%) and cyproterone compound (58.7%). For the HCW group the next most common formulations provided were levonorgestrel (96.0%), triphasics (91.3%), high-dose generics (58.0%) and Marvelon, Yasmin, Desoceptive and cyproterone compound (all < 10%). The main reasons for recommendation of OCP reported by both groups was effectiveness (92.0% and 86.7% for HCW and pharmacists respectively). Other important reasons given by pharmacists were low price (64.0%), ease of use (63.3%), ease of availability (64.0%) and reversibility (62.7%). Other reasons given by HCW were ease of use (79.3%), ease of availability (72.0%), independence from husbands (61.3%), reversibility (58.8%) and low price (53.3%). The average maximum duration that pharmacists recommended for safe use of OCP was 43.3 (SD 30.0) months (range months) while this was 45.4 (SD 32.1) months (range months) according to HCW (P < 0.05). Pharmacists reported that they provided OCP mainly on prescription from clinicians (50.7%), while HCW themselves generally prescribed and provided OCP to users (76.7%). Knowledge about initiation and use of OCP The most common time for tablettaking recommended by both groups was night-time before sleeping (95.2% and 85.3% for HCW and pharmacists respectively). The opinions of pharmacists and HCW regarding the necessary questions to ask users about their health history before initiating OCP are shown in Table 1. Significantly more pharmacists recommended enquiring about users history of diabetes, hypertension, epilepsy, coagulation diseases, past breast cancer, migraine, gallbladder disease and depression and about surgery in the near future (P < 0.001). Significantly more HCW recommended enquiring about history of uterus infections and liver disease (P < 0.001). Around 85% of both groups knew the correct initiation method of OCP (P > 0.05) but only 72.7% and 47.3% of HCW and pharmacists respectively gave this information to the users (Table 2). About half of HCW and one-third of pharmacists knew what action users should take if they forgot to take 1 tablet of low- or high-dose monophasic OCPs but fewer knew what users should do about 2 or more missed pills (33.3% and 31.9%, respectively, P > 0.05). Despite this obvious lack of knowledge, the proportions giving were fairly high (72.0% versus 50.7% respectively). Only 65.7% and 54.0% of HCW and pharmacists knew the correct action for 1 missed triphasic pill but much fewer knew what users should do about 2 missed triphasic pills (20.1% Table 1 Pharmacists and health-care workers (HCW) knowledge about which health problems to enquire about prior to initiation of oral contraceptive pills Health problems % agreeing it is important to ask about problem P-value HCW (n = 150) Pharmacists (n = 150) Diabetes < Hypertension < Seizures or epilepsy < Coagulation disease < Breast cancer (past) < Breast cancer (current) Family history of breast cancer Endocervical cancer Uterus infection < Migraine headache < Surgery in near future < Gallbladder disease < Depression < Liver disease <
4 EMHJ Vol. 19 No Eastern Mediterranean Health Journal La Revue de Santé de la Méditerranée orientale Table 2 Pharmacists and health-care workers (HCW) knowledge and practice of about different topics concerning oral contraceptive pill (OCP) use and side-effects Knowledge item HCW (n = 150) Pharmacists (n = 150) Start OCP from 5th day of period and take 1 each day, 1 week gap, start a new pack % Instructions for initiating and use of OCP P-value a % P-value a < Correct Incorrect No response If user forgets to take 1: monophasic OCP, she should take Correct tablet tablets > 2 tablets Incorrect No response If user forgets to take 1: triphasic OCP, she should take 2 tablets, if less than 12 h Correct Incorrect No response Non-contraceptive benefits of OCP OCP should make periods lighter Correct Incorrect No response OCP should make periods less painful Correct Incorrect No response OCP and acne: continue tablet use and no need to visit doctor Correct Incorrect No response Use of OCP with certain other medications causes problems Potential problems of OCP Correct Incorrect No response If user does not have period after end of pack: start next pack on time and visit a doctor Correct Incorrect No response
5 املجلة الصحية لرشق املتوسط املجلد التاسع عرش العدد السادس Table 2 Pharmacists and health-care workers (HCW) knowledge and practice of about different topics concerning oral contraceptive pill (OCP) use and side-effects (continued) Knowledge item HCW (n = 150) Pharmacists (n = 150) If user feels pain in thigh or calf: visit a doctor % P-value a % P-value a Correct Incorrect No response If user feels severe headache: take a pain killer and visit a doctor Correct Incorrect No response If user gets break-through bleeding: continue OCP and visit a doctor OCP side-effects Correct Incorrect No response If user feels breast tenderness: continue OCP and visit a doctor Correct Incorrect No response If user has nausea/vomiting: take OCP with food/with antiemetic/another time Correct (at least 1 correct answer) Incorrect No response OCP user s weight stays constant over time Controversies/ myths regarding OCP Correct Incorrect No response Users chances of having children is unaffected by OCP use Correct Incorrect No response OCP use causes dry mouth Correct Incorrect No response Health risks of OCP Smoking increases OCP risks Correct Incorrect No response
6 EMHJ Vol. 19 No Eastern Mediterranean Health Journal La Revue de Santé de la Méditerranée orientale Table 2 Pharmacists and health-care workers (HCW) knowledge and practice of about different topics concerning oral contraceptive pill (OCP) use and side-effects (concluded) Knowledge item HCW (n = 150) Pharmacists (n = 150) OCP decreases breast cancer and ovarian cancer risks % P-value a % P-value a Correct Incorrect No response OCP increases endocervical cancer risk < Correct Incorrect No response a Comparing total number to item versus number giving about item. and 16.3%). Despite this lack of knowledge 68.7% and 35.3% of HCW and pharmacists respectively gave advice to the users. Knowledge about noncontraceptive benefits of OCP Pharmacists and HCWs knowledge regarding the non-contraceptive benefits of OCP was determined by 3 questions (Table 2). While only 74.0% of pharmacists knew OCP could reduce bleeding during monthly periods, this was known by 94.7% of HCW (P < 0.001). Advising users about this information was done by HCW more than pharmacists (62.7% versus 22.0%). About 93.4% of HCW knew that OCPs could reduce menstrual pain but only 65.4% advised users about this topic. For pharmacists knowledge about this subject was 72.0% and providing was 26.0%. About 60% of both groups knew that appearance of new acne was not OCPrelated or even serious and did not require a visit to a physician (P < 0.05). The proportions who gave advice were reasonably high (45.9% and 30.7% for HCW and pharmacists respectively). Knowledge about potential problems with OCP Almost 90% of both groups knew that drug drug interaction with OCP could occur with some but not all medications (Table 2). However, only 35.3% of pharmacists provided information to users about this issue. The level of advice by HCW was twice as high (P < 0.05). Only half of HCW and pharmacists knew that when there was no menstrual bleeding at the end of a pack of OCP it was necessary to start a new pack and also to visit a doctor but 36.7% and 20.1% of HCW and pharmacists respectively recommended starting a new pack and not visiting a doctor, while 12.0% and 24.3% of HCW and pharmacists recommended stopping tablets altogether. About 80% of both groups knew that visiting a doctor was necessary when there if users had pain or oedema in the thigh or calf and 19.4% and 66.0% respectively of pharmacists and HCW said that they provided this information to users (P < 0.05). In case of severe headaches, 56.6% and 62.0% of HCW and pharmacists respectively thought that users should take pain killers and visit their doctor (P < 0.05) while only 37.8% and 20.1% of HCW and pharmacists knew that OCP should be discontinued. Despite this lack of knowledge, 65.3% and 16.1% of HCW and pharmacists said they would provide advice to users. Knowledge about OCP sideeffects A majority of HCW and pharmacists (52.7% and 62.0% respectively) knew that breakthrough bleeding could occur during OCP use and also that users should continue tablet-taking and visit a physician if the problem persisted (P < 0.01) (Table 3); 32.0% and 17.1% of HCW and pharmacists thought there was no need for a physician s visit and 14.0% of HCW and 16.2% of pharmacists believed that OCP should be stopped immediately. Pharmacists knew that taking the tablets with food (28.0%) or with an antiemetic (21.0%) or at a different time of day (30.0%) could diminish OCP induced nausea and vomiting and only 4.0% recommended discontinuation of these medications and a physician visit. HCWs knew that taking the tablets with food (39.3%) or with an antiemetic (56.0%) or at a different time of day (6.0%) could diminish OCP induced nausea and vomiting and but only 10.7% said users should see a physician, while 70.1% of HCW and 42.0% of pharmacists said they provided users with this information.. Of the HCW and pharmacists 42.7% and 48.0% respectively correctly believed that breast tenderness did not need a physician visit or discontinuation 552
7 املجلة الصحية لرشق املتوسط املجلد التاسع عرش العدد السادس Table 3 Pharmacists and health care workers (HCW) knowledge about recommendations for regular check-ups for users of oral contraceptive pills Health check-ups of OCP. Although about 50% of the respondents in both groups believed users should visit a physician and about 17.0% believed they should stop taking tablets, 66.7% and 16.0% HCW and pharmacists respectively gave information about this side-effect to users (P < 0.001). Knowledge about other recommendations during OCP use A great majority of HCW and pharmacists (89.6% and 70.0% respectively) knew that smoking could increase the risks associated with OCP but only 62.0% and 12.0% provided this information to users (P < 0.001) (Table 3). While 41.3% and 30.0% of HCW and pharmacists knew that OCP could reduce ovarian and uterine cancers respectively, almost 40% of both group wrongly believed OCP could increase the risk of these cancers. Despite this lack of knowledge 58.7% of HCW said they provided users with information on these subjects. In the case of endocervical cancer, 67.3% of the respondents in HCWs group and 48.7% of pharmacists knew that OCP could increase the risk but still in HCWs and pharmacists groups, 15.1% and 30.1% thought a decreased chance of breast cancer could occur by OCP use. The rate of about this issue among the HCW % agreeing it is necessary to perform check-up HCW (n = 150) Pharmacists (n = 150) and pharmacists was 52.0% and 14.7% respectively. The percentages of HCW and pharmacists who recommended physical examination of various organs for patients taking OCP are shown in Table 3. Significantly more HCW than pharmacists recommended regular checkups for heart and lung function, hypertension, weight, cervical smear, varicose veins, coagulation problems, lipid profile and thyroid profile. Knowledge about controversies or myths concerning OCP P-value Heart and lung function < Hypertension < Breast examination Weight < Cervical smear test Varicose veins < Coagulation problems Lipid profile < Thyroid problems < Although 76.7% of pharmacists and 81.4% of HCW believed that OCP could increase users body weight only about 15% of both groups believed it did not cause any weight changes and < 3% of the respondents thought it could decrease weight; 70.0% and 21.3% of HCW and pharmacists gave information regarding possible changes in body weight to users (Table 2). Whereas 82.0% and 60.7% of HCW and pharmacists believed that OCP use did not have an effect on a woman s future child-bearing (P < 0.001), 9.0% and 17.9% thought it would reduce the possibility of having children in the future; 67.3% and 20.1% of HCW and pharmacists counselled users about this subject (P < 0.001). On the issue of dry mouth 32.6% and 42.0% of HCW and pharmacists believed that dry mouth caused by OCP was not an indication for drug discontinuation and could be solved by drinking extra water. Interestingly 52.6% and 15.4% of HCW and pharmacists said they had provided users with this untrue information. Discussion This study compared 2 groups of professionals: HCW, who were midwives and family/public health educators, and pharmacists engaged in community or hospital outpatient pharmacies. As shown in the results there were differences between these groups in the level and type of education, but there are also differences in the type and frequency of continuing education, type of clientele and responsibilities, types and prices of OCP dispensed and level of workload. HCW receive training for family planning in nursing and midwifery schools and also have monthly classes to update their information. Pharmacists are trained in schools of pharmacies and have continuing medical education after graduation, which rarely covers OCP-related topics. These could affect providers knowledge and advice to users as seen from the results of this study. The study highlighted 2 problems; one was the lack of or low level of knowledge about OCP and the other was the low level of of OCP users. When there is insufficient knowledge among providers, users will not receive information on how to use OCP, what to do when a problem occurs or which signs they should be looking out for. In the case of pharmacists, we saw a lower level of knowledge in many areas of OCP usage, side-effects, signs of problem and contraindications than for HCW. There were also areas of poor knowledge among the HCW but these were less concerning than in the pharmacists group. In other words, HCW 553
8 EMHJ Vol. 19 No Eastern Mediterranean Health Journal La Revue de Santé de la Méditerranée orientale had a higher level of knowledge compared with pharmacists. Furthermore, HCW were more often providing to users compared with the pharmacists. Nevertheless, not all knowledge resulted in, which shows deficiencies in communication with OCP users. This might be as a result of lack of communication skills due to lack of training [9,10], an unsuitable environment for and a high number of clientele or responsibilities. Similar results were observed in previous studies in which pregnant women in Islamic Republic of Iran reported obtaining information from HCW rather than pharmacists [11 13]. When occurs with appropriate knowledge, it is useful for users and could improve the efficacy of OCP use, but serious problems could occur when the health care providers are about areas where their knowledge is poor. This means users could receive information that is incorrect and potentially dangerous. By offering further education and training for providers of OCP, and improving providers knowledge, the value of the offered will improve. Health professionals including pharmacists need better training in communication and for patients. Improved techniques, combined with a better knowledge level about OCP use, side-effects and lifethreatening problems, could improve patients compliance with OCP use and hence reduce the problem of unwanted pregnancies. Acknowledgements The present study is the output of the PharmD thesis of Dr Zeynab Mokhtari (thesis No 3532, registered in Faculty of Pharmacy, Tabriz University of Medical Sciences). Competing interests: None declared. References 1. Nielsen R. The little green handbook: seven trends shaping the future of our planet. New York, Picador, Lutz W, Sanderson W, Scherbov S. Doubling of world population unlikely. Nature, 1997, 387: Moos MK, Bartholomew NE, Lohr KN. Counseling in the clinical setting to prevent unintended pregnancy: an evidencebased research agenda. Contraception, 2003, 67: Vakilian K, Mirzaii K, NajmAbadi. Reproductive health in iran: international conference on population and development goals. Oman Medical Journal, 2011, 26: Islamic Republic of Iran: country profile. World Health Organization, Regional Office for the Eastern Mediterranean [online database] ( y&vid=10600 /, accessed 3 April 2013). 6. Aghajanian A, Mehryar AH. Fertility transition in the Islamic Republic of Iran: Asia-Pacific Population Journal, 1999, 14: Unwanted pregnancy rate drops in Iran. News number: July Fars News Agency [online] ( english.farsnews.com/newstext.php?nn= , accessed 3 April 2013). 8. Gaudet LM et al. What women believe about oral contraceptives and the effect of counseling. Contraception, 2004, 69: Hargie OD, Morrow NC, Woodman C. Pharmacists evaluation of key communication skills in practice. Patient Education and Counseling, 2000, 39: Greenhill N et al. Analysis of pharmacist patient communication using the Calgary Cambridge guide. Patient Education and Counseling, 2011, 83: Mashayekhi SO et al. Study of awareness among pregnant women of the effects of drugs on the fetus and mother in Iran. Health Policy, 2009, 91: Mashayekhi SO et al. Beliefs and practices of Iranian pregnant mothers regarding vitamins and minerals. Eastern Mediterranean Health Journal, 2011, 17: Mashayekhi SO, Dilmaghanizadeh M, Ghandforoush-Sattari M. A survey on the consumption, knowledge and attitude of pregnant women toward the effects of folic acid on pregnancy outcome in Iran. Iranian Journal of Child Neurology, 2011, 5:
progestog progestogen stogen-only pill progestogen progestogen-only pill he progestogen-only pill progestogen-onl progestogen-o the progestogenonly
your guide to the progestogenonly pill Helping you choose the method of contraception that is best for you the progestogen rogestogen-only the progestogen-only pill progestogen-only pill stogen-only progestoge
FDA-Approved Patient Labeling
FDA-Approved Patient Labeling Guide for Using Lo Loestrin Fe WARNING TO WOMEN WHO SMOKE Do not use Lo Loestrin Fe if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious
WOMENCARE A Healthy Woman is a Powerful Woman (407) 898-1500. Birth Control Pills
Birth Control Pills WOMENCARE A Healthy Woman is a Powerful Woman (407) 898-1500 Birth control pills (also called oral contraceptives or "the pill") are used by millions of women in the United States to
Combination Birth Control Pills - FAQ
Combination Birth Control Pills - FAQ How does the birth control pill work? prevents ovulation thickens cervical mucus, which makes it hard for sperm to enter the uterus thins the lining of the uterus,
Post-Coital Hormonal Contraception Instructions for Use of Plan B, Plan B One-Step, Next Choice One Dose, My Way, Generic Levonorgestrel and Ella
Post-Coital Hormonal Contraception Instructions for Use of Plan B, Plan B One-Step, Next Choice One Dose, My Way, Generic Levonorgestrel and Ella Several options for emergency birth control exist for women
implant contraceptiv contraceptive contraceptive raceptiv contraceptive implant contraceptive contraceptive ontraceptive implant ontraceptive im
your guide to the contraceptive implant Helping you choose the method of contraception that is best for you contra ontraceptive im contraceptive implant mpl ceptive contraceptive contracepti ntraceptive
Diary Card. Cerazette. Keeping a record. For women prescribed Cerazette. How do I find out more? www.cerazette.co.uk
Cerazette Keeping a record How do I find out more? You can ask for more information on Cerazette at your doctor s surgery or at family planning clinics. A diary card is attached. We suggest you keep a
PILLS & RING INFORMATION AND INSTRUCTIONS ON COMBINED HORMONAL CONTRACEPTION INCLUDING BIRTH CONTROL PILLS & NUVA RING
PILLS & RING INFORMATION AND INSTRUCTIONS ON COMBINED HORMONAL CONTRACEPTION INCLUDING BIRTH CONTROL PILLS & NUVA RING What is combined hormonal contraception? Birth control which contains two hormones
ency emergency contra-
your guide to emergency contraception Helping you choose the method of contraception that is best for you emergency cont gency contrace emergency contraception ency emergency contra- emergen mergency contraception
Risk Management Plan
Risk Management Plan Active substance: Drospirenone/ethinylestradiol Version number: 4.0 VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Oral contraception Effective control
injections injections injections injections injections injection injections injections injections tions njections injections injections injections
your guide to contraceptive Helping you choose the method of contraception that is best for you ions ections injection njections injection tions 2 Contraceptive Contraceptive contain a progestogen hormone
Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/ 0.03 mg
FDA Approved Patient Labeling Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/ 0.03 mg Rx only Guide for Using Drospirenone and Ethinyl Estradiol Tablets WARNING TO WOMEN WHO SMOKE Do not use drospirenone
The Challenges, Risks, and Benefits of Oral Contraceptives
The Challenges, Risks, and Benefits of Oral Contraceptives Learning Objectives After participating in this educational activity, participants should be better able to: 1. Identify the currently available
Combined Oral Contraceptives
CHAPTER Combined Oral Contraceptives Key Points for Providers and Clients y Take one pill every day. For greatest effectiveness a woman must take pills daily and start each new pack of pills on time. y
Overview of Existing State Distribution Mechanisms and Barr s Proposed Educational Program and Distribution for Plan B
Overview of Existing State Distribution Mechanisms and Barr s Proposed Educational Program and Distribution for Plan B In most states throughout the US, emergency contraception pills, including Plan B,
CYCLESSA Tablets (desogestrel and ethinyl estradiol tablets USP)
DETAILED PATIENT PACKAGE INSERT CYCLESSA Tablets (desogestrel and ethinyl estradiol tablets USP) 28 Day Regimen This product (like all oral contraceptives) is intended to prevent pregnancy. It does not
Hormonal Oral Contraceptives: An Overview By Kelsie Court. A variety of methods of contraception are currently available, giving men and
Hormonal Oral Contraceptives: An Overview By Kelsie Court A variety of methods of contraception are currently available, giving men and women plenty of options in choosing a method suitable to his or her
FDA-Approved Patient Labeling IMPLANON (etonogestrel implant) Subdermal Use
FDA-Approved Patient Labeling IMPLANON (etonogestrel implant) Subdermal Use IMPLANON does not protect against HIV infection (the virus that causes AIDS) or other sexually transmitted diseases. Read this
patch contracep raceptiv contraceptive patch contraceptive patch contraceptiv patch contraceptive patch tch ontraceptive atch contraceptive p
your guide to the contraceptive patch Helping you choose the method of contraception that is best for you contra ontraceptive pat contraceptive patch contraceptive patch ceptive patc atch contrace contracept
INFORMATION FOR THE PATIENT PATIENT PACKAGE INSERT CLÉO -35 Acne Treatment
INFORMATION FOR THE PATIENT PATIENT PACKAGE INSERT CLÉO -35 Acne Treatment Composition CLÉO -35 is a preparation which contains 2 sex hormones, cyproterone acetate and ethinyl estradiol in a specific ratio.
vagina vaginal r vaginal ring vaginal vaginal ring aginal ring vaginal ring vaginal ring vaginal ring the contraceptive vaginal rin vaginal ring
your guide to the contraceptive vaginal ring Helping you choose the method of contraception that is best for you vagina vaginal ring vaginal r vaginal ring vaginal ring vaginal rin vaginal aginal ring
A PATIENT S GUIDE TO DEEP VEIN THROMBOSIS TREATMENT
A PATIENT S GUIDE TO DEEP VEIN THROMBOSIS TREATMENT This medicine is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects, talk
Information for you Treatment of venous thrombosis in pregnancy and after birth. What are the symptoms of a DVT during pregnancy?
Information for you Treatment of venous thrombosis in pregnancy and after birth Published in September 2011 What is venous thrombosis? Thrombosis is a blood clot in a blood vessel (a vein or an artery).
Liver Disease & Hepatitis Program Providers: Brian McMahon, MD, Steve Livingston, MD, Lisa Townshend, ANP. Primary Care Provider:
Liver Disease & Hepatitis Program Providers: Brian McMahon, MD, Steve Livingston, MD, Lisa Townshend, ANP Primary Care Provider: If you are considering hepatitis C treatment, please read this treatment
Trileptal (Oxcarbazepine)
Brand and Generic Names: Trileptal Tablets: 150mg, 300mg, 600mg Liquid Suspension: 300mg/5mL Generic name: oxcarbazepine What is Trileptal and what does it treat? Trileptal (Oxcarbazepine) Oxcarbazepine
BACKGROUNDER CONTRACEPTION
BACKGROUNDER CONTRACEPTION DID YOU KNOW?» Approximately 85 out of 100 sexually active women who are not using any contraceptive method will get pregnant within one year. 1» Worldwide 38% of women who become
MEDICATION GUIDE COUMADIN (COU-ma-din) (warfarin sodium)
MEDICATION GUIDE COUMADIN (COU-ma-din) (warfarin sodium) Read this Medication Guide before you start taking COUMADIN (warfarin sodium) and each time you get a refill. There may be new information. This
MEDICAL HISTORY AND SCREENING FORM
MEDICAL HISTORY AND SCREENING FORM The purpose of preventive exams is to screen for potential health problems and provide education to promote optimal health. It is best practice for chronic health problems
Dr. Friedman s Guide to Estrogen Replacement
Dr. Friedman s Guide to Estrogen Replacement There are risks and benefits with all medicines and estrogen replacement is no exception. In fact, estrogen replacement is one of the most controversial topics
Now that your Doctor has prescribed Livial for you
Now that your Doctor has prescribed Livial for you This educational brochure is only for use by patients prescribed LIVIAL The Menopause The term menopause refers to the very last menstrual period a woman
MEDICATION GUIDE ACTOPLUS MET (ak-tō-plus-met) (pioglitazone hydrochloride and metformin hydrochloride) tablets
MEDICATION GUIDE (ak-tō-plus-met) (pioglitazone hydrochloride and metformin hydrochloride) tablets Read this Medication Guide carefully before you start taking and each time you get a refill. There may
Testosterone propionate, phenylpropionate, isocaproate and decanoate. Please read this leaflet carefully before you start using SUSTANON 250.
SUSTANON 250 Testosterone propionate, phenylpropionate, isocaproate and decanoate What is in this leaflet Please read this leaflet carefully before you start using SUSTANON 250. This leaflet answers some
contraception contraception contraception contracepti contraception contraception contraception aception contraception contraception contraception
your guide to Helping you choose the method of that is best for you raception aception contracept contracepti contracep contracepti Your guide to This leaflet shows the available contraceptive methods,
HCSP GUIDES A GUIDE TO: PREPARING FOR TREATMENT. A publication of the Hepatitis C Support Project
HCSP GUIDES T R E AT M E N T I S S U E S A publication of the Hepatitis C Support Project The information in this guide is designed to help you understand and manage HCV and is not intended as medical
This is Jaydess. Patient Information. What is Jaydess? How does Jaydess work?
, Patient Information This is Jaydess We hope that this brochure will answer your questions and concerns about Jaydess. What is Jaydess? Jaydess is an intrauterine device consisting of a hormone capsule
Rivaroxaban to prevent blood clots for patients who have a lower limb plaster cast. Information for patients Pharmacy
Rivaroxaban to prevent blood clots for patients who have a lower limb plaster cast Information for patients Pharmacy Your doctor has prescribed a tablet called rivaroxaban. This leaflet tells you about
ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR DEEP VEIN THROMBOSIS (DVT)
ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR DEEP VEIN THROMBOSIS (DVT) Information Leaflet Your Health. Our Priority. Page 2 of 6 What Are Anticoagulants And What Do They Do? This information leaflet
Why is Cerazette used? To prevent pregnancy.
CERAZETTE Tablets for oral use Consumer Medicine Information What is in this leaflet Keep this leaflet. You may need to read it again. This leaflet will provide information about the benefits and risks
Birth Control Options
1 of 5 6/2/2014 9:46 AM Return to Web version Birth Control Options What is contraception? Contraception means preventing pregnancy, also called birth control. Most people know about options such as birth
How Can We Get the Best Medication History?
How Can We Get the Best Medication History? Stephen Shalansky, Pharm.D., FCSHP Pharmacy Department, St. Paul s Hospital Faculty of Pharmaceutical Sciences, UBC How Are We Doing Now? Completeness of Medication
CONSUMER INFORMATION IMPORTANT: PLEASE READ
CONSUMER INFORMATION Pr MICRONOR norethindrone tablets, USP This leaflet is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about MICRONOR. Contact your
ALTERNATIVE TREATMENT PLAN AND CONSENT FOR MEDICAL ABORTION WITH MIFEPREX (MIFEPRISTONE) AND MISOPROSTOL
ALTERNATIVE TREATMENT PLAN AND CONSENT FOR MEDICAL ABORTION WITH MIFEPREX (MIFEPRISTONE) AND MISOPROSTOL The FDA gave its approval status to Mifepristone in 1996 based on research up to that time. Extensive
Effective long-lasting strategy to prevent unintended pregnancy. The intrauterine system for contraception after abortion.
Effective long-lasting strategy to prevent unintended pregnancy. The intrauterine system for contraception after abortion. After the abortion I started re-thinking my birth control method. I am looking
the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD your guide to
your guide to Helping you choose the method of contraception that is best for you IUD IUD the e IUD IU IUD the IUD 2 The intrauterine device (IUD) An IUD is a small plastic and copper device that is put
Original Research PRACTICE-BASED RESEARCH. School of Pharmacy, Philadelphia, PA
Market Diffusion of Extended Cycle Hormonal Contraceptives Megen Leeds Schumacher, Pharm.D. 1, Ashley Cetola Pettia, Pharm.D. 2, and Albert I Wertheimer, PhD, MBA, Professor 3 1 Pharmacy Practice, Regis
Risks Factors for Teenage Pregnancy and The Youth Perspective on Teenage Pregnancy and Health Needs in Nkalashane, Swaziland
Risks Factors for Teenage Pregnancy and The Youth Perspective on Teenage Pregnancy and Health Needs in Nkalashane, Swaziland 7 th Africa Conference on Sexual Health and Rights 8-12 February 2016 Background
PREMIER PLASTIC SURGERY CENTER OF NEW JERSEY 310 MADISON AVENUE, SUITE 100, MORRISTOWN, NJ 07960 PHONE: 973-889-9300 FAX: 973-889-9400
PREMIER PLASTIC SURGERY CENTER OF NEW JERSEY 310 MADISON AVENUE, SUITE 100, MORRISTOWN, NJ 07960 PHONE: 973-889-9300 FAX: 973-889-9400 Patient Information as of (todays date). Please print legibly and
IUD. the IUD. the IUD. the IUD. the IUD. the IUD. the IUD. the IUD. the IUD. the IUD. your guide to
your guide to Helping you choose the method of contraception that is best for you IUD he the the the 2 3 The intrauterine device (IUD) An IUD is a small plastic and copper device that is put into your
the abortion pill by David Hager, M.D.
the abortion pill by David Hager, M.D. A positive pregnancy test is one of the most life-changing moments for a woman. Never is it more important to base your decisions on accurate information. Try to
Informed Consent Form for Testosterone Therapy
Student Health Services Oregon State University, 201 Plageman Building, Corvallis, Oregon 97331-8567 Tel 541-737-9355 General Fax 541-737-4530 Medical Fax 541-737-9665 http://studenthealth.oregonstate.edu/
Delaying First Pregnancy
Delaying First Pregnancy Introduction The age at which a woman has her first pregnancy affects the health and life of a mother and her baby. While pregnancy can present health risks at any age, delaying
All methods of birth control are MUCH SAFER than being pregnant! If 100 women use each method for a year, how many of them get pregnant?
The Correct Use of Birth Control: In order for any method of birth control to be effective, it must be used correctly ALL THE TIME. This means: One condom every time you have sex One pill every day One
Polycystic Ovarian Syndrome
Polycystic Ovarian Syndrome What is Polycystic Ovarian Syndrome? Polycystic ovary syndrome (or PCOS) is a common condition affecting 3 to 5% of women of reproductive age. It is linked with hormonal imbalances,
Important Information About PRAMS Please Read Before Starting the Survey
Important Information About PRAMS Please Read Before Starting the Survey The Pregnancy Risk Assessment Monitoring System (PRAMS) is a research project conducted by the Bloustein Center for Survey Research
HIRSUTISM. What are the aims of this leaflet?
HIRSUTISM What are the aims of this leaflet? This leaflet has been written to help you understand more about hirsutism. It tells you what it is, what causes it, what can be done about it, and provides
ORAL ANTICOAGULANTS RIVAROXABAN (XARELTO) FOR PULMONARY EMBOLISM (PE)
ORAL ANTICOAGULANTS RIVAROXABAN (XARELTO) FOR PULMONARY EMBOLISM (PE) Information Leaflet Your Health. Our Priority. Page 2 of 6 What Are Anticoagulants And What Do They Do? This information leaflet has
A G U I D E F O R U S E R S N a l t r e x o n e U
A GUIDE FOR USERS UNaltrexone abstinence not using a particular drug; being drug-free. opioid antagonist a drug which blocks the effects of opioid drugs. dependence the drug has become central to a person
Drug prescription habits in public and private health facilities in 2 provinces in South Africa
Drug prescription habits in public and private health facilities in 2 provinces in South Africa G. Mohlala, 1 K. Peltzer, 1,2 N. Phaswana-Mafuya 1,3 and S. Ramlagan 1 عادات وصف األدوية يف املرافق الصحية
IUD. the IUD. the IUD. the IUD. the IUD. the IUD. the IUD the IUD. the IUD. the the IUD. the IUD. the IUD. the IUD. the IUD. the IUD.
your guide to Helping you choose the method of contraception that is best for you I the IUD 2 3 The intrauterine device (IUD) An IUD is a small plastic and copper device that is put into your uterus (womb).
117 4,904,773 -67-4.7 -5.5 -3.9. making progress
Per 1 LB Eastern Mediterranean Region Maternal and Perinatal Health Profile Department of Maternal, Newborn, Child and Adolescent Health (MCA/WHO) Demographics and Information System Health status indicators
The Morning-After Pill: The Dangers of Over-the-Counter Availability
The Morning-After Pill: The Dangers of Over-the-Counter Availability Hanna Klaus, M.D. ABSTRACT: In response to a request by Barr Laboratories to market their emergency contraceptive Plan B across the
USER PACKAGE LEAFLET: INFORMATION FOR THE USER Exluton, tablets 0.5 mg Lynestrenol
Lynestrenol 0.5mg tablets, (N.V.Organon), RH021 WHOPAR part 3 supplier s translation of original SRA approved text May 2012 USER PACKAGE LEAFLET: INFORMATION FOR THE USER Exluton, Lynestrenol Read this
Aetna Life Insurance Company
Aetna Life Insurance Company Hartford, Connecticut 06156 Amendment Policyholder: Group Policy No.: Effective Date: UNIVERSITY OF PENNSYLVANIA POSTDOCTORAL INSURANCE PLAN GP-861472 This Amendment is effective
Alcohol Screening and Brief Interventions of Women
Alcohol Screening and Brief Interventions of Women Competency #2 Midwest Regional Fetal Alcohol Syndrome Training Center Competency 2: Screening and Brief Interventions This competency addresses preventing
MS Treatments Aubagio TM
1 MSology Essentials Series Aubagio TM (teriflunomide) Developed by MSology with the invaluable assistance of multiple sclerosis nurse advisors: Bonnie Blain Central Alberta MS Clinic, Red Deer, Alberta
Understanding Fertility
Understanding Fertility 6 Introduction The word fertile means the ability to become pregnant or to cause pregnancy. Basic knowledge of both the male and female reproductive systems is important for understanding
Form ### Transgender Hormone Therapy - Estrogen Informed Consent SAMPLE
What are the different medications that can help to feminize me? Estrogen - Different types of the hormone estrogen can help you appear more feminine. Estrogen is the female sex hormone. Androgen blocker
UNDERGOING TERMINATION OF PREGNANCY AFTER 12 WEEKS
UNDERGOING TERMINATION OF PREGNANCY AFTER 12 WEEKS Information Leaflet Your Health. Our Priority. Page 2 of 5 The staff at Stepping Hill Hospital will support you as much as we can during this sad time.
Information for you Abortion care
Information for you Abortion care Published in February 2012 This information is for you if you are considering having an abortion. It tells you: how you can access abortion services the care you can expect
Preventive Care Guideline for Asymptomatic Low Risk Adults Age 18 through 64
Preventive Care Guideline for Asymptomatic Low Risk Adults Age 18 through 64 1. BMI - Documented in patients medical record on an annual basis. Screen for obesity and offer intensive counseling and behavioral
THE WELL. Intrauterine Contraceptive Devices WOMAN CENTRE
THE WELL WOMAN CENTRE Intrauterine Contraceptive Devices INTRAUTERINE CONTRACEPTIVE DEVICES How does the Mirena work? How effective is the Mirena? What are the advantages of the Mirena? What are the disadvantages
Ovarian Cyst. Homoeopathy Clinic. Introduction. Types of Ovarian Cysts. Contents. Case Reports. 21 August 2002
Case Reports 21 August 2002 Ovarian Cyst Homoeopathy Clinic Check Yourself If you have any of the following symptoms call your doctor. Sense of fullness or pressure or a dull ache in the abdomen Pain during
How To Write A Medical History Questionnaire For An Aransas Plastic Surgery
Arkansas Plastic Surgery O David H. Bauer, M.D. O Gary E. Talbert, M.D. Appointment Date Patient Information INFORMATION FOR CASE HISTORY FILE Patient s Name: SS# First Middle Last Date of Birth: Patient
Lamictal (lamotrigine)
Lamictal (lamotrigine) Important Warning : Serious skin rashes requiring medical hospitalization and discontinuation of treatment have been associated with Lamictal. Although rare, this rash (also known
World Health Day Diabetes and RMNCAH in Africa: R for Reproductive Health
World Health Day Diabetes and RMNCAH in Africa: R for Reproductive Health Managing diabetes and reproductive health in developing contexts. The 2016 World Health Day theme to scale up prevention, strengthen
Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital
Mahidol University Journal of Pharmaceutical Sciences 008; 35(14): 81. Original Article Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital
Patient Intake Form. Patient Information. How did you find out about our office?
Atlanta Injury and Wellness Center 2740 Greenbriar Parkway Suite A 3 Atlanta, GA 30331 404 629 9999 Patient Intake Form Welcome to our office of chiropractic. Thank you for taking a moment to fill in our
MEDICATION GUIDE. TOPAMAX (TOE-PA-MAX) (topiramate) Tablets and Sprinkle Capsules
MEDICATION GUIDE TOPAMAX (TOE-PA-MAX) (topiramate) Tablets and Sprinkle Capsules Read this Medication Guide before you start taking TOPAMAX and each time you get a refill. There may be new information.
Client Information for Informed Consent TESTOSTERONE FOR TRANSGENDER PATIENTS
Client Information for Informed Consent TESTOSTERONE FOR TRANSGENDER PATIENTS You want to take testosterone to masculinize your body. Before taking it, there are several things you need to know about.
Safe & Unsafe. abortion
Safe & Unsafe Facts About abortion WHAT IS THE DIFFERENCE BETWEEN UNSAFE AND SAFE ABORTION? What is unsafe abortion? Unsafe abortion is a procedure for terminating an unplanned pregnancy either by a person
POLYCYSTIC OVARY SYNDROME
POLYCYSTIC OVARY SYNDROME Information Leaflet Your Health. Our Priority. Page 2 of 6 What is polycystic ovary syndrome? (PCOS) Polycystic ovary syndrome (PCOS) is the most common hormonal disorder in women
PATIENT INFORMED CONSENT FOR APPETITE SUPPRESSANTS
PATIENT INFORMED CONSENT FOR APPETITE SUPPRESSANTS I, authorize Performance Weight Loss to assist me in my weight loss reduction efforts. I understand that my program consists of a balanced deficit diet,
LEFLUNOMIDE (Adults)
Shared Care Guideline DRUG: Introduction: LEFLUNOMIDE (Adults) Indication: Disease modifying drug for rheumatoid arthritis and psoriatic arthritis Licensing Information: Disease modifying drug for active
COI Research Management Summary on behalf of the Department of Health
COI Research Management Summary on behalf of the Department of Health Title: Worth Talking About Campaign Evaluation 2010 / 2011 Quantitative research conducted by TNS-BMRB COI Reference number: 114770
Understanding Your Risk of Ovarian Cancer
Understanding Your Risk of Ovarian Cancer A WOMAN S GUIDE This brochure is made possible through partnership support from Project Hope for Ovarian Cancer Research and Education. Project HOPE FOR OVARIAN
Medicines To Treat Alcohol Use Disorder A Review of the Research for Adults
Medicines To Treat Alcohol Use Disorder A Review of the Research for Adults Is This Information Right for Me? Yes, this information is right for you if: Your doctor* said you have alcohol use disorder
Script/Notes for PowerPoint Presentation. Medication Use Safety Training for Seniors (MUST for Seniors)
Script/Notes for PowerPoint Presentation Medication Use Safety Training for Seniors (MUST for Seniors) Instructions: You can use the following script to help you prepare your remarks to your organization
What Are Fertility Awareness Methods?
CHAPTER 17 Fertility Awareness Methods Key Points for Providers and Clients Fertility awareness methods require partners' cooperation. Couple must be committed to abstaining or using another method on
MALAWI YOUTH DATA SHEET 2014
MALAWI YOUTH DATA SHEET 2014 2 of Every 3 People in Malawi Are Under Age 25 Age 80+ 75-79 70-74 65-69 60-64 55-59 50-54 45-49 40-44 35-39 30-34 25-29 Male Female 20-24 POPULATION 700,000 700,000 0 POPULATION
MEDICATION GUIDE mitoxantrone (mito-xan-trone) for injection concentrate
MEDICATION GUIDE mitoxantrone (mito-xan-trone) for injection concentrate Read this Medication Guide before you start receiving mitoxantrone and each time you receive mitoxantrone. There may be new information.
INITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been
Ana M. Viamonte Ros, M.D., M.P.H. State Surgeon General
Florida Department of Health Division of Disease Control Bureau of Epidemiology Chronic Disease Epidemiology Section Charlie Crist Governor Ana M. Viamonte Ros, M.D., M.P.H. State Surgeon General Florida
Known Donor Questionnaire
Known Donor Questionnaire Your donor s answers to these questions will provide you with a wealth of information about his health. You ll probably need assistance from a health care provider to interpret
